With focus on fibrosis

R&D
R&D

PIPELINE

AnaMar AB has invented, and is developing a portfolio of novel high affinity, highly selective 5-HT2B receptor antagonists with potential use in a wide spread of human diseases, based on the receptors important role in a variety of pathological mechanisms.

AnaMar’s current focus is on fibrotic orphan indications and its lead project STING is developing first-in-class small-molecules for treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc), both diseases with poor prognosis.